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Purpose: To evaluate the efficacy of two-marker serum testing followed by
ultrasound for antenatal screening for trisomy 18.
Methods: Alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) data
from the maternal serum screening program at Taiwan Adventist Hospital were
collected for gestations between 15 and 21 weeks. We calculated the screening
positivity rate and sensitivity at various cutoff values. The results of fetal ultrasound
were also collected.
Results: With the cutoff values of maternal serum AFP ≤ 0.75 multiples of the
median (MoM) and hCG ≤ 0.55 MoM, two-marker testing yielded a sensitivity
of 88.9%, with a screening positivity rate of 3.5%. Using cutoff values of AFP
≤ 0.6 MoM and hCG ≤ 0.5 MoM, a much lower screening positivity rate with
similar sensitivity was found. Subsequent comprehensive ultrasound examination
may markedly reduce the need of amniocentesis.
Conclusions: We do not suggest offering routine amniocentesis to pregnant
women based on the results of two-marker testing for trisomy 18. Women with
positive serum test results should be carefully monitored with level II ultrasonography.
Amniocentesis is recommended only in cases of a positive serum screening result
and an abnormal fetal ultrasound.
(J Med Ultrasound 2002;10:26–31)
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INTRODUCTION
Trisomy 18 is a severe chromosomal aberration with
a prevalence rate of about 1 in 8,000 infants born
alive [1]. Fetuses with trisomy 18 have multiple
congenital abnormalities and growth restriction. Sev-
enty percent of such affected fetuses usually die in
utero. The remaining cases, in which the fetus thrives
and natural labor begins, have a high rate (≥ 50%)
of cesarean delivery if the trisomy is not diagnosed
antenatally [2].
The antenatal screening tools for trisomy 18
include second-trimester maternal serum markers
and ultrasonography. Fetuses with trisomy 18 are
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associated with low levels of maternal serum α-
fetoprotein (AFP), unconjugated estriol (uE3) and
human chorionic gonadotropin (hCG) [3–5]. Using
specific cutoff values for these three markers yields
a false-positive rate of 0.5% with a sensitivity of
85% [6, 7]. However, most laboratories in Taiwan
use two-marker (AFP and hCG), instead of three-
marker maternal serum screening for trisomies during
the second trimester of pregnancy. The efficacy of
two-marker testing for the antenatal screening of
trisomy 18 has never been evaluated.
The other powerful screening tool for the detec-
tion of trisomy 18 is ultrasound (US) because most
affected fetuses have multiple structural abnormalities,
polyhydramnios, severe growth restriction and el-
evated umbilical artery blood flow impedance [8, 9].
Most pregnant women undergo at least one antenatal
US paid by the National Health Insurance in Taiwan,
and most of the abnormalities would be found during
a comprehensive US examination.
The present study was designed to evaluate the
efficacy of two-marker maternal serum screening
followed by US for antenatal screening of trisomy
18 in Taiwan.
MATERIALS AND METHODS
A maternal serum screening program for triso-
mies using AFP and hCG was initiated at Taiwan
Adventist Hospital in June of 1994. Maternal
serum samples were drawn between 15 and 21
weeks of gestation and the markers measured by
commercially available microparticle enzyme
immunoassay kits (MEIA AFP kit and β-hCG kit,
Abbott Laboratories, North Chicago, IL, USA)
with a sensitivity of better than 0.4 ng/mL for
AFP and 2 ng/mL for β-hCG. The gestational age
of the pregnancy was determined by US meas-
urement of the fetal biparietal diameter (BPD)
[10]. The levels of maternal serum markers were
then converted to multiples of the median (MoM)
values for normal Taiwanese pregnant women at
the relevant gestational age after weight correc-
tion [11].
Initially we used the cutoff values of AFP ≤ 0.75
MoM and hCG ≤ 0.55 MoM. The test was consid-
ered positive for trisomy 18 if a patient’s serum level
for AFP was ≤ 0.75 MoM and, for hCG, ≤ 0.55
MoM. Genetic counseling and amniocentesis were
offered to the screening-positive women. We also
calculated the screening positivity rates and sensi-
tivities at various cutoff values.
The National Health Insurance system was in-
troduced in Taiwan in March of 1995 and provided
10 visits for antenatal care from 12 weeks of gestation
to term, including one fetal US scan between 20 and
24 weeks of gestation. Therefore, most pregnant
women received one or more US examinations during
their pregnancies after the introduction of National
Health Insurance. US scans were performed by one
of six experienced obstetrician sonographers using
an Acuson 128 XP machine (Acuson, Mountain
View, CA, USA) or an Aloka 2000 machine (Tokyo,
Japan). US examination included fetal biometry,
complexion, extremities and internal organs, as well
as amniotic fluid and placental measurement. All
neonates were carefully evaluated by pediatricians
to detect congenital anomalies. All fetuses with
chromosomal aberrations had confirmatory cytoge-
netic studies.
RESULTS
The data from 25,530 women were included in the
present study. The mean and median maternal ages
of the population were 29.46 ± 3.17 (SD) years
(range, 16–45 yr) and 29.56 years, respectively.
There were 1,520 women ≥ 34 years of age, com-
prising 6.0% of the study population. The mean and
median gestational ages were 17.27 ± 1.34 (range,
15–22 wk) and 17.1 weeks, respectively.
There were nine fetuses affected with trisomy 18.
With cutoff values for maternal serum AFP ≤ 0.75
MoM and hCG ≤ 0.55 MoM, 887 women screened
as positive, including eight women with trisomy 18
fetuses. Therefore, the screening-positive rate and
the sensitivity were 3.5% and 88.9% (8/9),
respectively. The results for various cutoffs of AFP
and hCG are listed in Table 1.
Among the 887 women with positive screening
results, 834 had antenatal US examinations (15–19
wk, 48; 20–24 wk, 719; 25–28 wk, 47; 29–35 wk,
20). Thirteen fetuses had abnormal findings, includ-
ing six with multiple malformations, three with
choroid plexus cysts (CPCs), one with polyhydr-
amnios, two with oligohydramnios and one with the
absence of stomach echoes. Antenatal US scans of
two affected fetuses are shown in Figures 1 and 2.
Three fetuses died in utero at 23, 23 and 37 weeks
of gestation, respectively. One fetus had a cleft
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palate, which was not detected on antenatal US. One
fetus had Down syndrome, but had no abnormal US
findings.
Among the eight women with a positive screen-
ing result, seven had US examinations. All seven
of these fetuses had abnormal ultrasonographic
findings, including five with multiple abnormalities
Table 1. Screening results of second-trimester maternal serum testing at various cutoff levels
Cutoff (MoM) No. screening-positives (%) % Sensitivity (n)
AFP ≤ 0.75; hCG ≤ 0.55 887 (3.5) 88.9 (8/9)
AFP ≤ 0.6; hCG ≤ 0.5 268 (1.2) 88.9 (8/9)
AFP ≤ 0.5; hCG ≤ 0.5 101 (0.4) 77.8 (7/9)
AFP x hCG ≤ 0.3 965 (4.3) 88.9 (8/9)
AFP x hCG ≤ 0.25 547 (2.4) 88.9 (8/9)
MoM = multiples of the median; AFP = α-fetoprotein; hCG = human chorionic gonadotropin.
Fig. 1. Sonogram of a 17-week fetus with trisomy 18.
A) Cross-sectional scan of the abdomen showing a large
omphalocele. B) Scan of the upper extremities shows the
absence of a forearm.
Fig. 2. Sonogram of a 22-week fetus with trisomy 18
showing a unilateral choroid plexus cyst (A, arrowhead),
endocardial cushion defect (B, asterisk) and rocker-bottom
foot (C, arrow).
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C
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and two with isolated CPC. The results are sum-
marized in Table 2.
DISCUSSION
Second trimester maternal serum screening for tri-
somies is now liberally used for antenatal screening
for Down syndrome. The efficacy of two-marker
screening using AFP and hCG is essentially similar
to that of triple-test screening using AFP, hCG and
uE3 [12, 13].
The application of maternal serum testing for
antenatal screening of trisomy 18 is a byproduct of
the Down syndrome screening program. The effi-
cacy of triple test screening for antenatal detection
of trisomy 18 is documented in the medical literature
[6]. Nonetheless, our study shows that two-marker
screening for trisomy 18 in the second trimester is
less effective than triple-test screening. When we
used the cutoff values for maternal serum AFP of
≤ 0.75 MoM and for hCG of ≤ 0.55 MoM, as used
in the triple test, the false-positive rate increased by
seven fold, from 0.5% in the triple test to 3.5% in
the two-marker test, but the detection rates were
similar. Using a lower cutoff of AFP ≤ 0.6 MoM
and hCG ≤ 0.5 MoM led to a much lower screen-
ing-positive rate of 1.2%, with similar sensitivity.
In the Down syndrome screening program, we
offer amniocentesis to women with high-risk results.
However, it is debatable whether or not we should
make a similar policy for the trisomy 18 serum
screening program. The prognoses of Down syn-
drome and trisomy 18 are quite different. Children
with Down syndrome may live long with mental
retardation and multiple congenital malformations,
but most fetuses with trisomy 18 die in utero or
immediately after birth, and the remainder seldom
survive 1 year after birth. The birth of a neonate
with Down syndrome has more profound psychologic
and economic impact on the families than does the
birth of a neonate with trisomy 18.
The option of invasive procedures is a trade-off
between the risk of the birth of an affected child
and the procedure-related losses of unaffected fetuses.
Table 2. Description of fetuses with trisomy 18
No. MA GA AFP (MoM) hCG (MoM) Genotype Ultrasound findings
1 31 16 0.47 0.45 47,XX,+18 Large CPC, polyhydramnios,
no stomach echo
2 31 15 0.55 0.35 47,XX,+18 Unilateral large CPC
3 23 15 0.43 0.23 47,XX,+18 Unilateral CPC
4 32 17 0.46 0.30 47,XX,+18 Bilateral CPC, large VSD,
rocker-bottom feet, clenched
hands
5 33 22 1.10 0.42 47,XX,+1 Clenched hands, micrognathia,
rocker-bottom feet
6 39 21 0.26 0.06 47,XX,+18 No check
7 27 15 0.39 0.17 47,XX,+18 SGA, unilateral large CPC,
ECD, reduction of both
forearms, absent stomach echo
8 29 15 0.49 0.19 47,XY,+18 Unilateral CPC, cleft lip, VSD,
single UA
9 26 17 0.34 0.24 47,XY,+18 Bilateral CPC, ECD, rocker-
bottom feet, clenched hands
MA = maternal age; GA = gestational age; AFP = α-fetoprotein; MoM = multiples of median; hCG = human chorionic
gonadotropin; CPC = choroid plexus cyst(s). VSD = ventricular septal defect; SGA = small for gestational age; ECD = endocardial
cushion defect; UA = umbilical artery.
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Amniocentesis is an invasive procedure. The esti-
mated fetal loss rate associated with amniocentesis
ranges from 0.5% and 1.0% [14]. In our study
population, we could have detected eight of nine
affected fetuses if we had offered amniocentesis to
the 887 women with positive screening results.
However, the estimated losses of unaffected fetuses
with 887 amniocenteses ranged from 4.4 to 8.8
fetuses (0.5% x [887–8] to 1.0% x [887–8]). This
translates into an estimated loss of 0.56 to 1.1
unaffected fetuses to reduce a single affected fetus
antenatally; in other words, an estimated loss of 1.
83 to 3.67 unaffected fetuses to detect a trisomy 18
neonate, because 70% of the affected fetuses die in
utero. When we used the cutoff values of AFP ≤
0.6 MoM and hCG ≤ 0.5 MoM, the estimated loss
of unaffected fetuses remained at 0.5 to 1.1 to
reduce a trisomy 18 neonate. Therefore, it is un-
reasonable to perform amniocentesis on all women
with positive screening results for trisomy 18.
Fetuses with trisomy 18 usually have multiple
congenital malformations and growth retardation.
Nyberg et al showed that 72% (21/29) of trisomy
18 fetuses had one or more detectable abnormalities
on ultrasonography before 24 weeks of gestation [9].
In the present study, seven of the eight affected
fetuses had ultrasonographic examinations during
weeks 20 to 22 of gestation, and all of them had
one or more identifiable structural abnormalities. In
Taiwan, the National Health Insurance provides a
routine antenatal US screening during weeks 20 to
24 of gestation. If we take the policy of two-marker
serum testing followed by US, only 14 cases had
both congenital abnormalities on antenatal US or
postnatal examination and a positive serum screen-
ing test. Therefore, 14 amniocenteses would be
needed to detect the seven of nine (78.9%) affected
fetuses. The policy of two-marker serum screening
followed by US markedly reduces the need for
amniocentesis and the procedure-related fetal loss
associated with it.
There is a debate that US examination itself
would provide a useful screening tool for trisomy
18. Without maternal serum screening, most fetuses
with trisomy 18 could be detected by antenatal US.
In the present study, isolated CPC was the only
abnormal US finding in two affected fetuses. Yoder
et al reported a likelihood ratio for trisomy 18 of
13.8 in fetuses with isolated CPC [15]. However,
many authors suggest that amniocentesis should be
recommended only in fetuses having CPC as well
as other additional risk factors, but not in fetuses
with isolated CPC [16, 17]. A positive serum screen-
ing test result provides an additional risk factor in
these two situations, which warrants the need for
amniocentesis. The combination of US and two-
marker serum testing is more effective than an
individual test. None, or only a small extra cost, is
inherent with the combined US and maternal serum
screening test because serum testing is a part of the
Down syndrome screening program and ultrasonog-
raphy is a routine examination paid for by the National
Health Insurance.
In conclusion, the present study shows that two-
marker maternal screening using AFP and hCG
is not as effective as is triple testing for second-
trimester screening of trisomy 18. We do not suggest
offering routine amniocentesis to pregnant women
based on the results of the two-marker serum screen-
ing test. The combination of two-marker testing and
ultrasonography may markedly improve the efficacy
of antenatal screening for trisomy 18. Therefore,
women with positive serum screening results should
have follow-up level II fetal ultrasonography to detect
potential fetal abnormalities.
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